1800 202 8726
Bladder cancer chemotherapy

GemCis and MVAC — Chemotherapy for Bladder Cancer

If your treatment plan shows GemCis or MVAC and nobody has explained what those letters mean, this page does that. Both are chemotherapy regimens for bladder cancer that has grown into the muscle wall.

  • GemCis is two drugs — Gemcitabine and cisplatin — a combination now listed as preferred in guidelines over the older MVAC.
  • MVAC is four drugs — Methotrexate, vinblastine, doxorubicin, and cisplatin — still used, particularly in a dose-dense form.
  • Given before surgery, usually — Both are neoadjuvant regimens — given before bladder removal — in current guidance for muscle-invasive disease.
  • Kidney function is a requirement — Both contain cisplatin, which requires adequate kidney function before it can be given safely.

Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed September 2026

Prescription-only medicine. GemCis and MVAC are prescription-only chemotherapy regimens that must be prescribed and supervised by a qualified oncologist. They cannot be started on the basis of anything read online or elsewhere. Nothing on this page is a recommendation to use this medicine. It is not suitable for most patients — see "Who this is not for" below.

Ask about your own treatment

A senior medical oncologist reviews what you send and replies in writing.

Reply within 2 working hours
Reviewed by a senior medical oncologist
Confidential. No commitment to start treatment.

GemCis (gemcitabine plus cisplatin) and MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) are chemotherapy regimens for muscle-invasive bladder cancer. GemCis is the more commonly used regimen today, per NCCN and ESMO guidance. Both are usually given before bladder surgery, and both require adequate kidney function because cisplatin must be cleared by the kidneys.

What do GemCis and MVAC stand for?

GemCis
Gemcitabine combined with cisplatin. A two-drug regimen listed as the preferred neoadjuvant option in current NCCN and ESMO guidance for muscle-invasive bladder cancer.
MVAC
Methotrexate, vinblastine, doxorubicin, and cisplatin. A four-drug regimen that was the earlier standard of care and remains in use, particularly as dose-dense MVAC.
Neoadjuvant
Chemotherapy given before surgery. In bladder cancer, this means treating the tumour before the bladder is removed.
Cisplatin-eligible
A clinical judgement that your kidney function, hearing, and overall fitness are sufficient for cisplatin to be given safely. Your oncologist makes this assessment before treatment begins.

Which of these regimens is used today?

GemCis is listed as the preferred neoadjuvant regimen in current NCCN and ESMO guidelines for muscle-invasive bladder cancer. It is now used more widely than the original four-drug MVAC.

Dose-dense MVAC — MVAC given on a shorter cycle with growth factor support — remains an accepted alternative in those same guidelines and is still used in practice.

Your oncologist's choice depends on your kidney function, general fitness, and the specifics of your disease.

How does neoadjuvant chemotherapy fit into bladder cancer treatment?

  1. Staging

    Scans and cystoscopy confirm that the cancer has grown into the bladder muscle. This is the finding that makes a patient a candidate for neoadjuvant treatment.

  2. Chemotherapy cycles

    You receive several cycles of GemCis or MVAC as an infusion, usually in a day-care oncology setting, over a number of weeks.

  3. Monitoring

    Blood tests during treatment track kidney function and blood counts. Your team adjusts the plan if needed based on those results.

  4. Restaging

    Scans are repeated after your final cycle to assess the tumour before surgery is scheduled.

  5. Surgery

    Radical cystectomy — removal of the bladder — takes place after you have recovered from chemotherapy. Your surgical team explains the urinary reconstruction options.

Who is not suitable for GemCis or MVAC?

Both GemCis and MVAC contain cisplatin, which limits who can safely receive them. Eligibility is always decided by an oncologist on the basis of your individual results, medical history, and current health.

These regimens are generally not used for people with:

  • Impaired kidney function — cisplatin depends on adequate kidney clearance and cannot be given safely below a threshold your oncologist will assess
  • Significant hearing loss, which cisplatin can worsen
  • Pre-existing peripheral neuropathy — numbness or tingling in the hands or feet
  • A performance status that makes intensive chemotherapy unsafe
  • Certain heart or liver conditions that affect how these drugs can be given
  • Non-muscle-invasive bladder cancer, where these regimens are not part of standard management

If you do not meet the criteria for cisplatin, your oncologist will discuss the available alternatives for your situation.

Can GemCis or MVAC be given after surgery instead of before?

Yes. Adjuvant chemotherapy — given after surgery rather than before — is considered when the surgical pathology shows features that raise concern about residual disease.

Current NCCN and ESMO guidance recommends the neoadjuvant approach as standard for eligible patients. Adjuvant treatment is typically considered when neoadjuvant chemotherapy was not given or was not possible.

Your oncologist will explain which timing applies in your case and the reasoning behind it.

What happens if your kidney function rules out cisplatin?

Both regimens depend on adequate kidney function because cisplatin is cleared through the kidneys. If your function is below the threshold your oncologist uses, cisplatin cannot be given safely.

Being ineligible for cisplatin is not the same as being ineligible for treatment. Your oncologist will discuss the chemotherapy combinations and other approaches available in that situation.

What else do people ask about GemCis and MVAC?

Why has GemCis become the more widely used regimen?

GemCis came to be considered to have a more manageable side effect profile than the original four-drug MVAC, while being regarded as similarly active for muscle-invasive bladder cancer. Both NCCN and ESMO reflect this in their guidelines by listing GemCis as the preferred option. Dose-dense MVAC remains listed as an accepted alternative and continues to be used in the right clinical circumstances.

What is dose-dense MVAC, and how is it different from standard MVAC?

Dose-dense MVAC gives the same four drugs as standard MVAC — methotrexate, vinblastine, doxorubicin, and cisplatin — but on a shorter cycle with a growth factor injection to support blood cell recovery between cycles. It was developed to reduce the cumulative burden of the original, more drawn-out treatment course. NCCN and ESMO both list it as an accepted alternative to GemCis for neoadjuvant treatment of muscle-invasive bladder cancer.

Does neoadjuvant chemotherapy mean I will definitely lose my bladder?

These regimens are most commonly paired with radical cystectomy — surgical removal of the bladder. Whether a bladder-preserving approach is relevant to your situation is a separate clinical decision, made by a specialist team, that does not apply to every patient. Your oncologist and urological surgeon will explain which surgical plan is being proposed for you and why.

Can these regimens be used when the cancer has spread beyond the bladder?

Cisplatin-based combinations including GemCis and MVAC are used for bladder cancer that has spread to lymph nodes or to distant sites as well. The treatment decisions and overall plan in that setting are different from the neoadjuvant context described on this page. Your oncologist will explain which approach applies based on the extent of disease shown on your imaging and other results.

Explore 82 more How Chemotherapy Is Given: Regimens, Cycles & Infusion Days topics

HUB — Chemotherapy Regimens

HUB — Cycles, Schedules and What Happens on Infusion Day

All How Chemotherapy Is Given: Regimens, Cycles & Infusion Days →

Common questions

Frequently asked questions

What is the difference between GemCis and MVAC?

GemCis uses two drugs — gemcitabine and cisplatin. MVAC uses four — methotrexate, vinblastine, doxorubicin, and cisplatin. GemCis is listed as the preferred neoadjuvant option in current NCCN and ESMO guidance, with dose-dense MVAC as an accepted alternative. The choice between them is made by your oncologist and depends on your kidney function, general fitness, and other individual factors.

Is neoadjuvant chemotherapy always given before bladder surgery?

It is recommended as standard for eligible patients by NCCN and ESMO, where cisplatin can be given safely. Not every patient can receive it — kidney function, performance status, and other factors determine eligibility. If neoadjuvant chemotherapy is not possible for you, your oncologist will explain the alternative treatment plan and what it is intended to achieve.

How many cycles of chemotherapy will I need?

A typical neoadjuvant course involves several cycles over a number of weeks, with rest periods between them. The planned number depends on your individual circumstances, including your tolerance of the treatment and your kidney function through the course. Your oncologist will give you the planned cycle count before you start. Cycle numbers are a plan, not a guarantee, and can be adjusted based on how treatment is going.

What are the main side effects I should know about?

Both regimens contain cisplatin, which can affect kidney function, cause nausea, and affect hearing and sensation in the hands and feet. Gemcitabine can reduce blood counts. MVAC adds methotrexate, vinblastine, and doxorubicin, each with their own effects. Your oncology team will explain which side effects are most relevant for your regimen and what to do if they occur. Never adjust or stop treatment because of a side effect without speaking to your team first.

Are these infusions given in hospital or at home?

These infusions are given in a clinical setting — usually as day care in an oncology centre — not at home. You come in for your infusion and return home the same day in most cases. The drugs require specialist preparation and monitoring during administration, which is why they are given in a supervised setting rather than sent home.

Can I ask for a second opinion on which regimen is recommended for me?

Yes, and it is entirely reasonable to do so. A second opinion does not mean rejecting your oncologist's care. A specialist at another centre will review the same pathology, imaging, and test results and either confirm the approach or suggest something different. Your existing team can usually arrange a referral, or you can ask your family doctor to help with this.

Full index

Browse all 579 chemotherapy topics

Every page in this section, grouped by the part of treatment it belongs to. Open a group to see what is in it.

Before You Start: Tests, Ports & Fertility42
Blood Counts, Infection, Fever & Emergencies73

Anaemia & Low Haemoglobin

HUB — Low Blood Counts, Infection and Fever During Chemotherapy

Chemotherapy and Supportive Medicines by Name75

Chemotherapy Drugs by Name

HUB — Chemotherapy Drugs by Name

HUB — Generic, Branded and Biosimilar Chemotherapy in India

HUB — Supportive Medicines Used With Chemotherapy

Chemotherapy at CION Cancer Clinics1
Chemotherapy by Cancer Type and Special Situations5

Special Populations & Comorbidities

HUB — Chemotherapy in Special Situations

Chemotherapy in Hyderabad: Cost, Centres & Access93

HUB — Choosing a Chemotherapy Centre and Safe Administration

Common Side Effects and How They Are Managed78
Food, Diet, Hydration & Household Safety6
How Chemotherapy Is Given: Regimens, Cycles & Infusion Days85

Other Ways Chemotherapy Is Given

HUB — Cycles, Schedules and What Happens on Infusion Day

Is It Working, Finishing Chemotherapy & Survivorship7

Is It Working? Response & Scans

HUB — Is Chemotherapy Working? Scans and Response

HUB — When Chemotherapy Stops Working

Nerve, Skin, Heart, Kidney and Cognitive Effects5

Skin, Nails & Hand-Foot Syndrome

Heart, Lung & Organ Toxicity

HUB — Effects on the Heart, Kidneys, Liver and Nerves

Understanding Chemotherapy, Myths & Trials97

HUB — Chemotherapy Myths and Alternative Treatment Claims

HUB — Clinical Trials in Cancer Treatment

HUB — What Is Chemotherapy and Why Has It Been Advised?

Work, Family, Relationships and Emotional Support12